封面
市场调查报告书
商品编码
1179875

2023 年至 2030 年干燥综合征的全球市场

Global Sjogren's Syndrome Market - 2023-2030

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内(2023 年至 2030 年),干燥综合征的市场规模预计将以 4.2% 的复合年增长率增长。

眼睛干涩和口干是干燥综合征 (SS) 的典型症状,这是一种免疫系统疾病。 这种综合征通常与其他免疫系统疾病并存,例如狼疮和类风湿性关节炎。 在干燥综合征中,口腔和眼睛的粘膜以及分泌水的腺体首先受到影响,导致唾液和泪液分泌减少。 这种疾病在女性中更为常见。 治疗的目标是缓解症状。

市场动态

推动干燥综合征全球市场发展的主要因素是干燥综合征和其他自身免疫性疾病的患病率增加、意识的提高、对尖端治疗的需求以及强大的药物管道。这些都有助于扩大市场。

干燥综合征和其他自身免疫性疾病正变得越来越普遍,预计将推动市场增长。

干燥综合征 (SS) 的主要症状是口干和眼干。 该病可发生于任何年龄,但常在中年开始逐渐恶化。 干燥综合征是当免疫系统攻击人体自身组织和器官时发生的自身免疫性疾病之一。 在干燥综合征中,免疫系统主要针对唾液腺和泪腺,限制它们产生眼泪和唾液的能力。 据估计,干燥综合征的发病率几乎是类风湿性关节炎 (RA) 的一半,影响 0.5% 至 1.0% 的人口。

国家生物技术信息中心 2022。 据估计,干燥综合征影响了 400,000 至 310 万成年人。 该病可发生于任何年龄,但平均发病年龄在45至55岁之间。 大约一半的患者还发现结缔组织疾病,例如类风湿性关节炎和狼疮。

Sjogren 在全世界的成人和儿童中很少见,发病率似乎没有任何种族或地域偏见。 然而,该病明显多见于女性,女性与男性的比例约为 9:1,与 SLE 相似。 本病好发于中年,也可发生于幼儿和老年人。

缺乏关于干燥综合征药物可用性的知识预计会阻碍市场增长。

然而,高昂的治疗费用和干燥综合征的影响(如急性脱水、快速体重减轻和炎症)将限制市场扩张。 在上述预测期内,由于缺乏对该疾病、其预防措施和药物副作用的了解,干燥综合症市场将面临挑战。

COVID-19 影响分析

在 Pandis 期间,大多数行业都经历了负面反应。 这是由于国际监管机构实施的各种预防性封锁和其他限制措施导致其製造和供应链发生重大中断。 市场也是如此。 大多数人的总体经济状况受到 Pandis 的严重影响,导致人们更倾向于从预算和消费需求中削减非必要支出。 预计这些因素将对本季度的市场产生不利影响。

人们也对提高多样化供应链的弹性以确保获得关键原材料产生了新的兴趣。 由于迫切需要批准新的 COVID-19 疫苗和治疗方法,监管机构正在简化评估和批准程序。 这些进步有望增加未来药物的临床和商业成功。 然而,一旦当局解除药物限制,全球干燥剂行业有望復苏。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 干燥综合征等自身免疫性疾病正变得越来越普遍
      • 对尖端医疗保健的认识和需求不断提高
    • 约束因素
      • 对干燥综合征药物的可用性了解不足
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章药物类别

  • 胆碱能激动剂
  • 标籤外药物

第 8 章按症状

  • 眼睛干涩
  • 口干舌燥

第9章按类型

  • 原发性干燥综合征
  • 继发性干燥综合征

第 10 章(按销售渠道)

  • 医院
  • 零售店
  • 在线药店

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • Novartis AG
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Allergan Inc
  • Otsuka Pharmaceutical Co., Ltd
  • Santen Pharmaceutical Co., Ltd.
  • Nicox S.A
  • Argentis Pharmaceuticals, LLC
  • Auven Therapeutics
  • Abbvie Inc
  • Cellzome GmbH.
  • Biogen In.

第 14 章干燥综合征-DataM 的全球市场

简介目录
Product Code: DMPH26

Market Overview

Sjogren's Syndrome Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.2% during the forecast period (2023-2030).

The two most typical symptoms of Sjogren's syndrome (SS), an immune system illness, are dry eyes and a dry mouth. The syndrome frequently coexists with other immune system diseases like lupus and rheumatoid arthritis. The mucosal membranes and moisture-secreting glands of the mouth and eyes are typically impacted first in Sjogren's syndrome, which causes less saliva and tears to be produced. In women, the illness is far more prevalent. The goal of treatment is to diminish symptoms.

Market Dynamics

The major factors driving the global sjogren's syndrome market are that Sjogren's syndrome and other autoimmune illnesses are becoming more common, increasing awareness and the need for cutting-edge medical care, additionally, a strong drug pipeline has contributed to the market's expansion

Sjogren's syndrome and other autoimmune illnesses are becoming more common and are expected to drive the market's growth.

The primary symptoms of Sjogren syndrome (SS) are dry mouth and eyes. The illness can happen at any age, but it often starts to worsen progressively in middle adulthood. Sjogren syndrome is one of a vast set of ailments known as autoimmune disorders that take place when the immune system targets the body's own tissues and organs. In Sjogren syndrome, the immune system predominantly targets the salivary glands and the lacrimal glands, which limit the glands' capacity to secrete tears and saliva. The incidence of Sjogren syndrome is close to half that of rheumatoid arthritis (RA), or it affects 0.5% to 1.0% of the population, according to

The National Centre for Biotechnology Information 2022. Sjogren's syndrome affects between 400,000 and 3.1 million adult people. Although this illness can affect individuals of any age, the average onset of symptoms is between the ages of 45 and 55. Rheumatoid arthritis and other connective tissue illnesses, such lupus, are also present in about half of patients.

Sjogren has been recorded in adults and children less frequently throughout the world, and there doesn't seem to be any racial or geographic bias in incidence. However, the disorder has a clear preference for females, and similar to SLE, the female: male ratio is around 9:1. The condition typically manifests in middle age, but it can also affect young children and the elderly.

Lack of knowledge regarding the availability of the Sjogren's syndrome drug is expected to hamper the market's growth.

However, the high cost of treatment and sjogren's disease consequences such acute dehydration, rapid weight loss, and inflammation will restrain market expansion. During the aforementioned projection period, the sjogren's syndrome market will face challenges from a lack of knowledge regarding the condition, its preventative measures, and drug side effects.

COVID-19 Impact Analysis

During the Pandamic, most industries experienced negative repercussions. This can be attributed to significant disruptions in their manufacturing and supply chains as a result of various preventative lockdowns and other limitations imposed by international regulatory organizations. The market is the same. The general economic status of the majority of people has been severely hit by the pandamic, which has also resulted in a fall in consumer demand as people are more inclined to eliminate non-essential expenditure from their budgets. During the projected period, it is anticipated that the aforementioned factors will have a negative impact on the market.

There is also a resurgence of interest in enhancing the resilience of diversified supply chains to provide reliable access to vital raw materials. Due to the urgent need to approve new COVID-19 vaccines and therapies, regulatory agencies have simplified the evaluation and approval processes. It is hoped that these advancements will increase the clinical and commercial success of future medicines. However, it is projected that the worldwide Sjogren syndrome (SS) industry will recover once the relevant governing authorities start pharmaceuticals lift such imposed lockdowns.

Segment Analysis

The hospital's segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Hospitalization rates were greater for SS patients than for the general population. Patients with SS were more likely than comparators to be hospitalized for endocrine/metabolic illnesses, cardiovascular diseases, musculoskeletal diseases, connective tissue disorders, and traumas. People with Sjogren's disease are more likely to need inpatient hospital care for infections picked up in the community, especially those of the lungs and intestines, according to Sjogren's syndrome News from October 2022. Hospitalizations for opportunistic infections, such as mycobacterium infections and the chickenpox/shingles virus (zoster), are also more common in this patient population. Sjogren's patients had a 98% higher overall hospitalization rate for a first infection than healthy individuals did.

According to experts from the University of Montpellier in France, while the effect of infections on outcomes related to other autoimmune illnesses has been extensively discussed, little is known regarding the prevalence of severe infections necessitating hospitalization in Sjogren's patients.

Geographical Analysis

North America holds the largest market share in the global Sjogren's Syndrome market.

North America dominates the global Sjogren's syndrome market primarily due to its large population, excellent medical infrastructure, and high-income levels. Around 1 in 200 Americans are thought to be affected by Sjogren's syndrome, according to the Johns Hopkins Sjogren's Center 2021. A team of knowledgeable professionals must evaluate patients who believe they may have Sjogren's syndrome. The doctors at the Jerome Greene Sjogren's syndrome Center at Johns Hopkins have great experience in Sjogren's syndrome diagnosis, treatment, and research. Their knowledge is currently centralized in a facility easily accessible on the Johns Hopkins Bayview campus in Baltimore, Maryland. Rheumatologists, ophthalmologists, neurologists, and gynecologists make up the company team and review 200-300 new patients with a suspected or confirmed diagnosis of Sjogren's syndrome each year.

Additionally, many businesses are there, and the syndrome that propels the region is developing. For instance, in September 20222, advancement prospects increase once Novartis completes a Phase II Sjogren's syndrome trial. The team at Clinical Trials Arena also looks at a leishmaniasis trial suspension, a lymphoma trial termination, and trial completions for endometriosis and dry eye syndrome. Remibrutinib (LOU-064) from Novartis saw an increase in its Phase Transition Success Rate (PTSR) of eight points to 34% in Sjogren's syndrome following the conclusion of Phase II research.

Competitive Landscape

The sjogren's syndrome market is moderately competitive with local and global companies' presence. Novartis AG, Allergan Inc, Otsuka Pharmaceutical Co., Ltd, Santen Pharmaceutical Co., Ltd., Nicox S.A, Argentis Pharmaceuticals, LLC, Auven Therapeutics, Abbvie Inc Cellzome GmbH, Biogen Inc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in November 2022, For those with autoimmune and chronic inflammatory disorders, including Sjogren's syndrome, Motto Health has opened a kind of virtual clinic with rheumatologists and medical specialists, the startup revealed. The technology enables patients to manage and track symptoms, schedule virtual consultations with physicians, and obtain individualized treatment regimens using an online application.

Novartis AG.

Overview: A healthcare firm called Novartis AG (Novartis) specializes in the development, production, and marketing of prescription and over-the-counter medicines, as well as products for eye care. Among other things, it offers medicines for the treatment of infections, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory illnesses, and cancer. Through Sandoz, the business provides biosimilars and generic medications. Through The Novartis Institutes for BioMedical Research, Novartis carries out research in a number of illness areas (NIBR).

Product Portfolio:

Hydroxychloroquine (Plaquenil): The anti-rheumatic medicine hydroxychloroquine (Plaquenil) is a disease-modifying medication (DMARD). It can lessen arthritic pain and swelling. It might stop joint deterioration and lessen the possibility of permanent impairment. The drug hydroxychloroquine belongs to a group of drugs that were initially used to treat and prevent malaria.

Key Development: In September 2022, Sjogren's syndrome Phase II trial by Novartis is now complete. After that, they suspend the Phase I study for visceral leishmaniasis, end the Phase I trial for B-cell lymphoma, and complete the Phase I trials for endometriosis and dry eye syndrome.

The global Sjogren's Syndrome market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Sjogren's syndrome and other autoimmune illnesses are becoming more common
      • 4.1.1.2. Increasing awareness and the need for cutting-edge medical care
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of knowledge regarding the availability of the Sjogren's syndrome drug
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Cholinergic Agonists
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Off-Label Drugs

8. By Symptoms

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 8.1.2. Market Attractiveness Index, By Symptoms
  • 8.2. Dry eyes
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Dry mouth

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Primary Sjogren's Syndrome
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Secondary Sjogren's Syndrome

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospitals
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacy
  • 10.4. Online Pharmacy

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Novartis AG
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Allergan Inc
  • 13.3. Otsuka Pharmaceutical Co., Ltd
  • 13.4. Santen Pharmaceutical Co., Ltd.
  • 13.5. Nicox S.A
  • 13.6. Argentis Pharmaceuticals, LLC
  • 13.7. Auven Therapeutics
  • 13.8. Abbvie Inc
  • 13.9. Cellzome GmbH.
  • 13.10. Biogen In.

LIST NOT EXHAUSTIVE

14. Global Sjogren's Syndrome Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us